04:59 PM EDT, 08/22/2025 (MT Newswires) -- Devonian Health Group ( DVHGF ) , a clinical-stage corporation focused on developing unique solutions to inflammatory diseases, provided a corporate update and additional information on a previously announced private placement after-hours on Friday.

On the manufacturing front, the Thykamine batch-to-batch consistency has been validated through advanced analytical techniques, and pre-clinical programs are progressing to demonstrate its "unique dual action" on both inflammation and fibrosis pathways.

Additionally, Devonian Health ( DVHGF ) is advancing the development of oral formulations to unlock additional opportunities in Ulcerative Colitis and other diseases where oral delivery is preferred.

The company also stated that a U.S. survey of dermatologists confirmed the acceptance of Thykamine cream in pediatric patients with mild-to-moderate atopic dermatitis.

Furthermore, the distribution license for Dexlansoprazole was not renewed and expired on April 17, 2025. The company also confirmed that the agreement for Pantoprazole Magnesium -- the second product licensed from the same partner, representing approximately 10.6% of revenues for the fiscal year ended July 31, 2024, and 4.2% for the nine-month period ended April 30, 2025 -- will terminate on April 23, 2026. The corporation said it will continue to market and sell Pantoprazole Magnesium until that date, maintaining revenue contributions in the interim. "At the same time, management is carefully evaluating strategic options for this business unit."

Devonian Health ( DVHGF ) has also provided corrections regarding the details of a private placement announced on August 7, 2025. The company has stated that gross proceeds, disclosed as C$2,272,999.85, should have been C$2,362,999.80, and the 15,153,332 units stated should have been 15,753,332.

Shares of Devonian Health Group ( DVHGF ) were last seen $0.16 on the TSX Venture Exchange.